Literature DB >> 11438744

A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation.

M M Kim1, M A Rivera, I L Botchkina, R Shalaby, A D Thor, E H Blackburn.   

Abstract

The ribonucleoprotein telomerase synthesizes telomeric DNA by copying an intrinsic RNA template. In most cancer cells, telomerase is highly activated. Here we report a telomerase-based antitumor strategy: expression of mutant-template telomerase RNAs in human cancer cells. We expressed mutant-template human telomerase RNAs in prostate (LNCaP) and breast (MCF-7) cancer cell lines. Even a low threshold level of expression of telomerase RNA gene constructs containing various mutant templates, but not the control wild-type template, decreased cellular viability and increased apoptosis. This occurred despite the retention of normal levels of the endogenous wild-type telomerase RNA and endogenous wild-type telomerase activity and unaltered stable telomere lengths. In vivo tumor xenografts of a breast cancer cell line expressing a mutant-template telomerase RNA also had decreased growth rates. Therefore, mutant-template telomerase RNAs exert a strongly dominant-negative effect on cell proliferation and tumor growth. These results support the potential use of mutant-template telomerase RNA expression as an antineoplastic strategy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438744      PMCID: PMC35454          DOI: 10.1073/pnas.131211098

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Telomere states and cell fates.

Authors:  E H Blackburn
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

2.  Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2.

Authors:  D Broccoli; A Smogorzewska; L Chong; T de Lange
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

3.  Extension of life-span by introduction of telomerase into normal human cells.

Authors:  A G Bodnar; M Ouellette; M Frolkis; S E Holt; C P Chiu; G B Morin; C B Harley; J W Shay; S Lichtsteiner; W E Wright
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

4.  TRF2 protects human telomeres from end-to-end fusions.

Authors:  B van Steensel; A Smogorzewska; T de Lange
Journal:  Cell       Date:  1998-02-06       Impact factor: 41.582

5.  Cap-prevented recombination between terminal telomeric repeat arrays (telomere CPR) maintains telomeres in Kluyveromyces lactis lacking telomerase.

Authors:  M J McEachern; E H Blackburn
Journal:  Genes Dev       Date:  1996-07-15       Impact factor: 11.361

6.  Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability.

Authors:  L Marusíc; M Anton; A Tidy; P Wang; B Villeponteau; S Bacchetti
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

7.  Block in anaphase chromosome separation caused by a telomerase template mutation.

Authors:  K E Kirk; B P Harmon; I K Reichardt; J W Sedat; E H Blackburn
Journal:  Science       Date:  1997-03-07       Impact factor: 47.728

8.  Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA.

Authors:  S Kondo; Y Kondo; G Li; R H Silverman; J K Cowell
Journal:  Oncogene       Date:  1998-06-25       Impact factor: 9.867

9.  Rap1 protein regulates telomere turnover in yeast.

Authors:  A Krauskopf; E H Blackburn
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

10.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.

Authors:  T Kiyono; S A Foster; J I Koop; J K McDougall; D A Galloway; A J Klingelhutz
Journal:  Nature       Date:  1998-11-05       Impact factor: 49.962

View more
  42 in total

1.  Molecular targeting of cancer: telomeres as targets.

Authors:  R Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 2.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

3.  Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands.

Authors:  J F Riou; L Guittat; P Mailliet; A Laoui; E Renou; O Petitgenet; F Mégnin-Chanet; C Hélène; J L Mergny
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

4.  Preferential maintenance of critically short telomeres in mammalian cells heterozygous for mTert.

Authors:  Yie Liu; Hue Kha; Mark Ungrin; Murray O Robinson; Lea Harrington
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 5.  Telomeres and telomerase.

Authors:  Simon R W L Chan; Elizabeth H Blackburn
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-01-29       Impact factor: 6.237

6.  Telomerase can act as a template- and RNA-independent terminal transferase.

Authors:  Neal F Lue; Dimitry Bosoy; Tara J Moriarty; Chantal Autexier; Brian Altman; Siyang Leng
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-30       Impact factor: 11.205

7.  Comprehensive structure-function analysis of the core domain of human telomerase RNA.

Authors:  Hinh Ly; Elizabeth H Blackburn; Tristram G Parslow
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 8.  Budding yeast for budding geneticists: a primer on the Saccharomyces cerevisiae model system.

Authors:  Andrea A Duina; Mary E Miller; Jill B Keeney
Journal:  Genetics       Date:  2014-05       Impact factor: 4.562

9.  A novel pseudoknot element is essential for the action of a yeast telomerase.

Authors:  Yehuda Tzfati; Zachary Knight; Jagoree Roy; Elizabeth H Blackburn
Journal:  Genes Dev       Date:  2003-06-27       Impact factor: 11.361

Review 10.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.